Form 4: ClearPoint Neuro Director Pascal Girin Receives Equity Grant of 12,417 Restricted Stock Units

ClearPoint Neuro, Inc. announced that Director Pascal E. R. Girin was granted 12,417 restricted stock units, aligning his interests with shareholders.

Summary

• Pascal E. R. Girin, a Director of ClearPoint Neuro, Inc. (CLPT), was granted 12,417 Restricted Stock Units (RSUs).
• The transaction date for this grant was May 22, 2025.
• Each RSU represents a contingent right to receive one share of ClearPoint Neuro, Inc. common stock.
• The RSUs will vest on the earlier of May 22, 2026 (the first anniversary of the grant date) or the day immediately preceding the Company's 2026 annual meeting of stockholders.
• Following this transaction, Mr. Girin beneficially owns 12,417 restricted stock units directly.

Sentiment

Score: 6

Explanation: The document reports a routine equity grant to a director, which is generally viewed positively as it aligns management/director interests with shareholders, but it does not contain information that would significantly alter the company's financial outlook or operations.

Positives

• The grant of Restricted Stock Units to Director Pascal E. R. Girin aligns his financial interests with those of the company's shareholders, incentivizing long-term performance.
• Equity compensation is a common and effective way to retain and motivate key personnel, including directors.

Future Outlook

The document does not contain any forward-looking statements or guidance beyond the vesting schedule of the granted restricted stock units.

Industry Context

The grant of restricted stock units to a director is a common practice in the biotechnology and medical device industries, serving as a form of equity compensation to align the interests of board members with long-term shareholder value creation. This type of compensation is widely used across publicly traded companies to attract and retain qualified directors.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as director compensation is a standard practice across various industries, including medical technology, aligning director incentives with company performance and shareholder returns.
• While the specific number of RSUs granted (12,417) is company-specific, the mechanism of granting equity at a $0 acquisition price with a time-based vesting schedule (one year or next annual meeting) is consistent with typical non-employee director compensation packages observed in companies of similar size and stage within the medical device sector.
• Comparable companies like Inari Medical, Inc. (NARI) or Penumbra, Inc. (PEN) also frequently utilize equity grants, including RSUs or stock options, as a significant component of their non-executive director compensation to foster long-term commitment and ownership.

Corporate Governance

Related Party Transactions

• The grant of Restricted Stock Units to Director Pascal E. R. Girin constitutes a related party transaction as it involves compensation to a member of the company's board of directors. This is a standard and disclosed form of compensation.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's interests with shareholders, potentially leading to better long-term decision-making focused on increasing shareholder value.
• Employees: No direct impact on employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Next Steps

• The granted Restricted Stock Units are expected to vest on the earlier of May 22, 2026, or the day immediately preceding ClearPoint Neuro, Inc.'s 2026 annual meeting of stockholders.

Key Dates

Keywords

ClearPoint Neuro, CLPT, Form 4, Restricted Stock Units, RSU, Equity Grant, Director Compensation, Insider Transaction, Pascal Girin